Genomic Health Expanding Sales Force by 20 Percent; Starts Prostate Dx Studies | GenomeWeb

By Edward Winnick

SAN FRANCISCO (GenomeWeb News) – Genomic Health officials today said that the firm has started the process of expanding its sales force by around 20 percent to help support the recent launch of its Oncotype DX DCIS Score test.

Speaking at the 30th Annual JP Morgan Healthcare Conference today, Genomic Health CEO Kim Popovits outlined the firm's efforts to expand the customer base for its Oncotype DX tests and announced that the company has launched a clinical validation study of its prostate cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.